<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03237819</url>
  </required_header>
  <id_info>
    <org_study_id>AOR16028</org_study_id>
    <nct_id>NCT03237819</nct_id>
  </id_info>
  <brief_title>Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive Care</brief_title>
  <acronym>MAGMAT</acronym>
  <official_title>Interest of Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive Care: Multicentric Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thrombotic Thrombocytopenic Purpura (TTP) is a potentially life-threatening thrombotic&#xD;
      microangiopathy caused by a severe deficiency of ADAMTS13 (a disintegrin and&#xD;
      metalloproteinase with a thrombospondin type 1 motif member 13). Decreased ADAMTS13 activity&#xD;
      leads to an accumulation of ultralarge von Willebrand factor (vWF) multimers which induce&#xD;
      aggregation of platelets and microthrombi. These microthrombi may involve the brain, heart,&#xD;
      kidneys and lead to life-threatening organ failures.&#xD;
&#xD;
      In experimental models, magnesium sulfate increases cleavage of newly released vWF by&#xD;
      ADAMTS13, decreases the endothelial secretion of ultralarge vWF and inhibits the interaction&#xD;
      of vWF with platelets. In another thrombotic microangiopathy, magnesium sulfate has been&#xD;
      shown to reduce the risk of seizures in women with severe pre-eclampsia. In analogy with its&#xD;
      evidence-based therapeutic application in pre-eclampsia and based on a strong rationale for&#xD;
      magnesium supplementation in TTP, we propose a phase 3, double blind, placebo controlled, and&#xD;
      randomized study to evaluate the efficacy of magnesium sulfate in more rapidly restoring&#xD;
      normal platelet counts as measure of prevention of further microvascular thrombosis in&#xD;
      patients with Thrombotic Thrombocytopenic Purpura.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 27, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>multicentre double-blind randomized clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>For each day of treatment, 4 ampoules of 10 ml will be distributed to the patient's nurse (4 ampoules of 1.5g of magnesium sulphate or 3 ampoules of 5% glucose as placebo).&#xD;
The bulbs will be labeled identically so that the blind can be maintained Moreover, in order to preserve the blind, the dosage of magnesemia should not be performed outside of a necessity judged by the clinician in charge of the patient</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time to normalization of the platelet count</measure>
    <time_frame>3 months</time_frame>
    <description>Normalization of the platelet is defined as a platelet count that reaches at least 150,000 per cubic millimeter for 48 consecutive hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration and volume of plasma exchanges</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>platelet count</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of subjects with refractory TTP</measure>
    <time_frame>5 days</time_frame>
    <description>absence of platelet count doubling after 4 days of standard treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with an exacerbation of TTP</measure>
    <time_frame>30 days</time_frame>
    <description>recurrence during the 30 days after the last daily plasma exchange</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a relapse of TTP</measure>
    <time_frame>3 months</time_frame>
    <description>recurrence occurring more than 30 days after the last daily plasma exchange</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac trouble frequency</measure>
    <time_frame>day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral trouble frequency</measure>
    <time_frame>day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute kidney injury</measure>
    <time_frame>day 30</time_frame>
    <description>Kidney Disease: Improving Global Outcomes (KDIGO) score &gt; or = 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to normalization of hemolysis marker levels</measure>
    <time_frame>day 30</time_frame>
    <description>Lactate dehydrogenase (LDH), haptoglobin, bilirubinemia, hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital mortality</measure>
    <time_frame>day 90</time_frame>
    <description>90 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events related to the use of magnesium sulfate</measure>
    <time_frame>day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Thrombotic Thrombocytopenic Purpura</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Glucose serum (3 ampoules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Magnesium Sulfate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20/5000 magnesium sulfate (4 ampoules, 1,5g each)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfate, Magnesium</intervention_name>
    <description>Magnesium sulphate will be administered at a dose of 6g over 20 min intravenously followed by a continuous infusion of 6g / 24h for 3 days.&#xD;
For each day of treatment, 4 ampoules of 10 ml will be distributed to the nurse in charge of the patient (4 ampoules of 1,5g of magnesium sulfate)</description>
    <arm_group_label>Magnesium Sulfate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - Concentrate</intervention_name>
    <description>For each day of treatment, 4 ampoules of 10 ml will be distributed to the nurse in charge of the patient (4 ampoules of glucose 5% as placebo)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; or = 18 years&#xD;
&#xD;
          -  Health insurance&#xD;
&#xD;
          -  Signed inform consent by patient or relatives&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  No health insurance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Saint Louis hospital</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 13, 2017</study_first_submitted>
  <study_first_submitted_qc>July 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2017</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thrombotic Thrombocytopenic Purpura</keyword>
  <keyword>Intensive care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombotic Thrombocytopenic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

